KLIFO A/S - CVR: 18196131

2023, DKK

02.05.2024

Bruttoresultat

105''

Primær drift

-5.553'

Årets resultat

5.896'

Aktiver

92.596'

Kortfristede aktiver

75.088'

Egenkapital

33.661'

Afkastningsgrad

-6 %

Soliditetsgrad

36 %

Likviditetsgrad

142 %

Resultat

02.05.2024

Årsrapport	2023 02.05.2024	2022 16.06.2023	2021 31.05.2022	2020 07.04.2021	2019 02.04.2020	2018 09.04.2019
Nettoomsætning
Bruttoresultat	104.647.000	132.185.000	121.967.000	107.430.000	81.067.000	70.084.547
Resultat af primær drift	-5.553.000	14.016.000	18.056.000	16.846.000	2.465.000	8.848.844
Indtægter af kapitalandele (tilknyttede og associerede)	0	-9.650.000	-10.690.000	-4.333.000	-1.774.000	0
Finansielle indtægter	1.099.000	607.000	167.000	50.000	14.000	724.637
Finansieringsomkostninger	-779.000	-1.220.000	-894.000	-498.000	-456.000	-164.030
Andre finansielle omkostninger	0	0	0	0	0	0
Resultat før skat	4.648.000	3.753.000	6.639.000	12.065.000	249.000	9.409.451
Resultat	5.896.000	832.000	2.838.000	8.445.000	-263.000	7.440.071
Forslag til udbytte	0	0	-7.500.000	-4.300.000	0	-3.700.000

Aktiver

02.05.2024

Årsrapport	2023 02.05.2024	2022 16.06.2023	2021 31.05.2022	2020 07.04.2021	2019 02.04.2020	2018 09.04.2019
Kortfristede varebeholdninger	0	0	0	0	0	0
Kortfristede tilgodehavender fra salg og tjenesteydelser	55.731.000	52.256.000	65.360.000	45.204.000	34.145.000	25.483.254
Likvider	19.357.000	28.772.000	66.791.000	13.781.000	2.908.000	11.261.268
Kortfristede aktiver	75.088.000	81.028.000	132.151.000	58.985.000	37.053.000	36.744.522
Immaterielle aktiver og goodwill	6.797.000	2.897.000	2.643.000	0	0	0
Finansielle anlægsaktiver	4.187.000	3.572.000	2.020.000	3.323.000	7.290.000	1.529.292
Materielle aktiver	6.525.000	5.392.000	6.444.000	6.515.000	3.917.000	2.427.650
Langfristede aktiver	17.509.000	11.861.000	11.107.000	9.838.000	11.207.000	3.956.942
Aktiver	92.596.000	92.889.000	143.258.000	68.823.000	48.260.000	40.701.464

Aktiver

02.05.2024

Passiver

02.05.2024

Årsrapport	2023 02.05.2024	2022 16.06.2023	2021 31.05.2022	2020 07.04.2021	2019 02.04.2020	2018 09.04.2019
Forslag til udbytte	0	0	7.500.000	4.300.000	0	3.700.000
Egenkapital	33.661.000	15.303.000	21.918.000	23.380.000	14.935.000	18.897.629
Hensatte forpligtelser	0	0	0	7.474.000	3.402.000	464.593
Langfristet gæld til banker	0	0	0	0	0	0
Anden langfristet gæld	6.181.000	0	6.105.000	6.713.000	0	0
Leverandører af varer og tjenesteydelser	24.926.000	32.357.000	10.752.000	0	0	9.143.337
Kortfristede forpligtelser	52.754.000	70.629.000	114.513.000	0	0	21.339.242
Gældsforpligtelser	0	0	0	37.969.000	29.923.000	21.339.242
Forpligtelser	0	0	0	37.969.000	29.923.000	21.339.242
Passiver	92.596.000	92.889.000	143.258.000	68.823.000	48.260.000	40.701.464

Passiver

02.05.2024

Nøgletal

02.05.2024

Årsrapport	2023 02.05.2024	2022 16.06.2023	2021 31.05.2022	2020 07.04.2021	2019 02.04.2020	2018 09.04.2019
Afkastningsgrad	-6,0 %	15,1 %	12,6 %	24,5 %	5,1 %	21,7 %
Dækningsgrad	Na.	Na.	Na.	Na.	Na.	Na.
Resultatgrad	Na.	Na.	Na.	Na.	Na.	Na.
Varelagerets omsætningshastighed	Na.	Na.	Na.	Na.	Na.	Na.
Egenkapitals-forretning	17,5 %	5,4 %	12,9 %	36,1 %	-1,8 %	39,4 %
Payout-ratio	Na.	Na.	264,3 %	50,9 %	Na.	49,7 %
Gældsdæknings-nøgletal	-712,8 %	1.148,9 %	2.019,7 %	3.382,7 %	540,6 %	5.394,6 %
Soliditestgrad	36,4 %	16,5 %	15,3 %	34,0 %	30,9 %	46,4 %
Likviditetsgrad	142,3 %	114,7 %	115,4 %	Na.	Na.	172,2 %

Resultat

02.05.2024

Gæld

02.05.2024

Årsrapport

02.05.2024

Nyeste:01.01.2023- 31.12.2023(offentliggjort: 02.05.2024)

Information om virksomhedens regnskabsklasse:The annual report of KLIFO A/S for 2023 has been prepared in accordance with the provisions in the Danish Financial Statements Act applying to reporting class C middle sized entities.

Oplysning om eventualaktiver:Contractual obligations and contingencies, etc. Other contingent liabilitiesThe Company was until May 17, 2021 jointly taxed with its parent company KLIFO Holding A/S and its ultimative parent company, Mørk Holding 2007 ApS, which acts as management company, and is jointly and severally liable with other jointly taxed group enterprises for payment of income taxes for the income year 2013 and onwards as well as withholding taxes on interest, royalties and dividends falling due for payment on or after 1 July 2012. From May 17, 2021 the company is jointly taxed with its parent company Drug Development Consulting BidCo ApS and its ultimative parent company, Drug Development Consulting Holding ApS, which acts as management company, and is jointly and severally liable with other jointly taxed group enterprises for payment of income taxes for the income year 2021 and onwards as well as withholding taxes on interest, royalties and dividends falling due for payment. Other financial obligations20232022Rent and lease liabilities19. 54521. 109Rent and lease liabilities include a building rent obligation totalling k. DKK 19. 332 with contract terms within 5 years. Furthermore, the Company has liabilities under operating leases for cars and other equipment.

Beretning

02.05.2024

Dato for ledelsens godkendelse af årsrapporten:2024-04-25

Ledelsespåtegning:Ledelsespåtegning

Statement by Management on the annual report

Identifikation af den godkendte årsrapport:Today, the Board of Directors and the Executive Board have discussed and approved the annual report of KLIFO A/S for the financial year 1 January ‑ 31 December 2023.

Management's review

Beskrivelse af virksomhedens væsentligste aktiviteter:Business reviewKLIFO Group is a drug development consultancy with significant experience in partnering with biotech and pharmaceutical companies to advance their drug development projects. KLIFO offers cross functional consulting and operational solutions spanning all areas of strategic advises, regulatory affairs, CMC development, clinical research, pharmacovigilance, clinical trial supply and quality assurance. Over the past decade, KLIFO has grown to become an established and integrated drug development consultancy providing end to end expert capabilities, enabling our partners to maximize opportunity, mitigate risks, drive innovation and achieve efficient project advancement. In 2023, the biotech market, particularly in the Nordics, faced significant challenges exacerbated by a constrained funding environment post-COVID, coupled with heightened interest and market volatility. These factors notably affected KLIFO during the first half of 2023, resulting in a decline in activity level compared to 2022. To adapt to the new market situation, KLIFO made organizational adjustments throughout 2023. Looking forward, KLIFO is witnessing a rise in activity levels and order book, projecting a return to business growth in 2024.